You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

CLINICAL TRIALS PROFILE FOR STALEVO 100


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Stalevo 100

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT01766258 ↗ Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations Completed Orion Corporation, Orion Pharma Phase 2 2011-05-01 The primary objective of the study is to assess the efficacy, carbidopa dose response and safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment of Parkinson's disease (PD) patients with end-of-dose motor fluctuations.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Stalevo 100

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00099268 ↗ Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Completed Orion Corporation, Orion Pharma Phase 3 2004-09-01 The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
NCT00099268 ↗ Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy Completed Novartis Pharmaceuticals Phase 3 2004-09-01 The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
NCT00125567 ↗ Stalevo in Early Wearing-Off Patients Completed Orion Corporation, Orion Pharma Phase 4 2005-08-01 The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Stalevo 100

Condition Name

Condition Name for Stalevo 100
Intervention Trials
Parkinson's Disease 11
Parkinson Disease 3
Parkinson´s Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Stalevo 100
Intervention Trials
Parkinson Disease 16
Sleep Wake Disorders 1
Parasomnias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Stalevo 100

Trials by Country

Trials by Country for Stalevo 100
Location Trials
United States 37
Canada 11
Italy 11
Finland 8
United Kingdom 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Stalevo 100
Location Trials
Michigan 3
Florida 3
California 3
Virginia 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Stalevo 100

Clinical Trial Phase

Clinical Trial Phase for Stalevo 100
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Stalevo 100
Clinical Trial Phase Trials
Completed 13
Not yet recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Stalevo 100

Sponsor Name

Sponsor Name for Stalevo 100
Sponsor Trials
Orion Corporation, Orion Pharma 10
Novartis Pharmaceuticals 2
IMPAX Laboratories, Inc. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Stalevo 100
Sponsor Trials
Industry 16
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

STALEVO 100: Clinical Trials, Market Analysis, and Projections

Introduction

STALEVO 100 is a medication used in the treatment of idiopathic Parkinson's disease, combining carbidopa, levodopa, and entacapone. This article will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Purpose and Design

A significant clinical trial involving STALEVO is the prospective, multi-center, randomized open-label study with blinded raters. This study aims to evaluate the effects of immediate versus delayed switch to STALEVO on motor function and quality of life in patients with Parkinson's disease experiencing end-of-dose wearing off[1].

Inclusion and Exclusion Criteria

The study includes patients between 30-80 years of age with a clinical diagnosis of idiopathic Parkinson's disease and end-of-dose wearing off. They must be taking a stable dose of immediate-release carbidopa/levodopa 25/100 mg for at least one month prior to the study. Exclusion criteria include the use of nonselective MAOIs within two weeks and narrow-angle glaucoma[1].

Treatments and Dosage

The study involves various strengths of STALEVO, including 50, 100, 125, 150, and 200 mg formulations, each containing a fixed ratio of carbidopa to levodopa and 200 mg of entacapone. The dosage is individualized, with a maximum of 8 tablets per day for most strengths and 6 tablets per day for the 200 mg strength[2][4].

Market Analysis

Indications and Usage

STALEVO 100 is indicated for the treatment of idiopathic Parkinson's disease, particularly to substitute for equivalent doses of previously administered carbidopa/levodopa and entacapone, and to replace immediate-release carbidopa and levodopa in patients experiencing end-of-dose "wearing-off" symptoms[4].

Market Position

STALEVO, as a combination therapy, holds a significant position in the Parkinson's disease treatment market due to its ability to extend the period of action of levodopa alone. This makes it a preferred option for managing motor symptoms and improving quality of life in patients with Parkinson's disease[2].

Competitive Landscape

The Parkinson's disease treatment market is competitive, with other drugs like Xadago (safinamide) also being used to manage symptoms. However, STALEVO's unique combination and efficacy profile give it a distinct advantage in the market[3].

Safety and Efficacy

Safety Profile

Clinical trials and post-market analysis have shown that STALEVO has a generally favorable safety profile, although it can have side effects such as dyskinesias and an addictive pattern of dopamine dysregulation syndrome. Contraindications include the use of nonselective MAOIs and narrow-angle glaucoma[5].

Efficacy

The efficacy of STALEVO in managing motor symptoms and improving quality of life has been well-documented. The drug helps in reducing the "wearing-off" phenomenon, thereby providing more consistent symptom control throughout the day[1][4].

Market Projections

Demand and Growth

The demand for STALEVO is expected to grow due to the increasing prevalence of Parkinson's disease and the need for effective management of its symptoms. The global Parkinson's disease treatment market is projected to expand, driven by advancements in treatment options and an aging population[3].

Pricing and Accessibility

STALEVO is available in various strengths, and its pricing can vary based on the formulation and market. Generic availability of STALEVO 100 has made it more accessible to patients, contributing to its market share[4].

Regulatory Environment

Approvals and Compliance

STALEVO has been approved for use in treating Parkinson's disease, and its use is regulated by health authorities to ensure safety and efficacy. The drug must be used in accordance with the approved indications and dosage guidelines[5].

Patient Impact

Quality of Life

STALEVO significantly improves the quality of life for patients with Parkinson's disease by reducing the frequency of "wearing-off" symptoms and providing more consistent control over motor symptoms. This leads to better mobility and reduced disability[1].

Patient Satisfaction

Clinical trials have shown high patient satisfaction with STALEVO due to its effectiveness in managing symptoms and improving daily functioning. Patient feedback highlights the drug's ability to enhance their overall well-being[1].

Key Takeaways

  • Clinical Trials: Ongoing studies evaluate the immediate versus delayed switch to STALEVO, focusing on motor function and quality of life.
  • Market Analysis: STALEVO holds a strong position in the Parkinson's disease treatment market due to its efficacy and unique combination.
  • Safety and Efficacy: The drug has a favorable safety profile and is effective in managing motor symptoms and improving quality of life.
  • Market Projections: Growing demand driven by the increasing prevalence of Parkinson's disease and an aging population.
  • Regulatory Environment: Approved for use with specific indications and dosage guidelines.
  • Patient Impact: Significant improvement in quality of life and patient satisfaction.

FAQs

What is STALEVO 100 used for?

STALEVO 100 is used to treat idiopathic Parkinson's disease, particularly to manage end-of-dose "wearing-off" symptoms and to substitute for equivalent doses of previously administered carbidopa/levodopa and entacapone[4].

What are the main components of STALEVO 100?

STALEVO 100 contains 25 mg of carbidopa, 100 mg of levodopa, and 200 mg of entacapone[2].

What are the common side effects of STALEVO 100?

Common side effects include dyskinesias and an addictive pattern of dopamine dysregulation syndrome. It is also contraindicated in patients with narrow-angle glaucoma and those using nonselective MAOIs[5].

Can STALEVO 100 be used in children?

No, the safety and effectiveness of STALEVO 100 have not been established in pediatric patients under 18 years of age[4].

How is STALEVO 100 administered?

STALEVO 100 should be swallowed whole, with a maximum of 8 tablets per day. The dosage should be individualized based on the patient's previous carbidopa/levodopa and entacapone regimen[4].

What is the expected market growth for STALEVO 100?

The market for STALEVO 100 is expected to grow due to the increasing prevalence of Parkinson's disease and the need for effective symptom management[3].

Sources

  1. Clinical Trials: "A prospective, multi-center study to evaluate the effects of immediate versus delayed switch to Stalevo® on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off"[1].
  2. Guideline Central: "Stalevo - Drug Information from Guideline Central"[2].
  3. Newron Valuation Report: "vL Newron Valuation Report 3JAN23.pdf"[3].
  4. eMPR: "STALEVO 100 Prescription & Dosage Information - eMPR.com"[4].
  5. Novartis Product Monograph: "PRODUCT MONOGRAPH PrSTALEVO* - Novartis"[5].
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.